ARTICLE | Clinical News
Humira adalimumab: Phase III data; marketed
February 2, 2004 8:00 AM UTC
Researchers published data from the double-blind, Phase III STAR trial in 636 patients that showed that there were no significant differences in adverse event rates between patients given 40 mg Humira...